Advanced Science
Cure8 research brief
Why This Matters
The paper identifies a new mechanism (VDAC1-driven mtDNA release activating cGAS–STING) that may drive inflammation in ulcerative colitis and a candidate compound (senkyunolide I) that blocks this pathway in preclinical models. If validated, this could point to new therapies for UC.
Who Should Pay Attention
Researchers, drug developers, and clinicians focused on UC immunology and novel therapeutics
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper (abstract provided) reports that senkyunolide I (SEI), a natural compound, reduced experimental colitis in mice by blocking a chain of immune events in macrophages: SEI binds VDAC1 (lysine-12), prevents its stress-induced oligomerization, stops mitochondrial DNA leaking into the cytosol, and thereby suppresses cGAS–STING signaling and downstream inflammasome activation and cell death pathways.
The authors validated parts of this mechanism in intestinal tissue, cultured macrophages, genetic overexpression models, and report that VDAC1 levels in UC patient samples correlate with cGAS–STING activation and disease severity. The study is presented as a mechanistic, preclinical investigation (advanced journal abstract).
It suggests VDAC1–cGAS–STING is a potential therapeutic target and that SEI is an experimental lead compound, not an approved treatment. The abstract is the basis for this summary; Cure8 did not review the full paper beyond the supplied abstract.
Keep In Mind
Findings are based on preclinical experiments (mouse models, cells) and an abstract-level summary; clinical relevance is suggested by correlations in patient tissue but not proven.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAdvanced Science
PublisherWiley
AuthorsZhiming Ye, Yihang Huang, Bohao Han +7 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 7, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Benzoylpaeoniflorin regulates macrophage polarization via the RNF31-DPEP2 axis to ameliorate intestinal mucosal barrier damage in ulcerative colitis.
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible...
Microbial metabolite hyodeoxycholic acid induces macrophage immunometabolic reprogramming and alleviates ulcerative colitis.
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
Dehydrodiisoeugenol ameliorates DSS-induced ulcerative colitis by suppression of cellular senescence through inhibiting AKT and activating GSK3B.
The study identifies a compound (DDIE) that reduced cellular senescence and improved colitis in a mouse model by modulating AKT and GSK3B, suggesting a new avenue for drug development in ulcerative colitis focused on...